Model free audit methodology for bias evaluation
of tumour progression in oncology.
Stone A, Macpherson E, Smith A,
Jennison C Pharmaceutical Statistics 2015 14:455-463
When is a seamless study desirable?
Case studies from different pharmaceutical sponsors.
Cuffe RL, Lawrence D, Stone A, Vandemeulebroecke M. Pharmaceutical Statistics 2014 13: 229-237
Can a treatment be licensed on the basis of post
treatment predictive biomarkers?
Stone A, Schmitt N. Pharmaceutical Statistics 2014 13: 214-221
Strong control over multiple endpoints: are we adding value to the assessment of medicines?
Stone A, Chuang-Stein C. Pharmaceutical Statistics
2013 12: 189-191
Missing data and censoring in the analysis of progression free survival in oncology clinical trials.
Denne J, Stone A, Bailey-Iacona R, Chen T. J
Biopharmaceutical Statistics 2013 23: 951-970
Attenuation of treatment effect due to measurement variability in assessment of progression-free survival.
Hong S, Schmitt N, Stone A, Denne J.
Pharmaceutical Statistics 2012 11: 394-402
Immunotherapy Trial Design
What are the implications for trial design, sizing, analysis and interpretation if the treatment effect is delayed
Adaptive Trial Design
Experience and learning from one of the first adaptive trials performed in oncology
Biomarkers and Subgroups
How to establish which patients benefit most from therapy
Progression Free Survival
How to best design and analyse your trial when using PFS
Phase II trial design
The benefits of randomisation even with small patient numbers
Here are some sample presentations. In most cases the work has subsequently been published in peer-reviewed journals.
On this page you can find a full list of citations.
Manuscripts published in peer review journals on trial design and methodology in a regulatory setting